GUILLERMO
LÓPEZ VIVANCO
Forscher bis um 2022
Hospital Vall d'Hebron
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Vall d'Hebron (9)
2023
2022
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology, Vol. 71
-
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Journal for immunotherapy of cancer, Vol. 10, Núm. 9
2021
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8
-
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
-
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Scientific Reports, Vol. 5
2012
2003
-
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: A multicentre phase II study
Lung Cancer, Vol. 39, Núm. 2, pp. 201-207